Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders
Amount Raised
$20 Million
Round Type
Funding Round
FraminghamInformation TechnologyBiotechnologyCommunity And LifestyleHealth CareScience And EngineeringDescription
Variantyx, a leader in high complexity hereditary disease testing, today announced that they secured $20M in funding for their Whole Genome Sequencing (WGS)-based testing methodology, an advanced genetic testing method currently used to diagnose rare inherited and neurological disorders. The series C funding round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners. Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.
Quick answer
Variantyx raised $20 Million in a Funding Round round, dated March 15, 2021. Variantyx is based in Framingham, Massachusetts, United States.
- How much did Variantyx raise?
- Variantyx raised $20 Million in a Funding Round round on March 15, 2021.
- What does Variantyx do?
- Variantyx is a technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets.
- Where is Variantyx based and how big is it?
- Variantyx is based in Framingham, Massachusetts, United States.
- Who are the decision-makers at Variantyx?
- Fundz holds 1 contact at Variantyx, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Community And Lifestyle and Science And Engineering around the same time
Companies in the same sectors as Variantyx that raised within 45 days of this round, from Fundz verified event records.
- Trait Biosciences Inc. raised $12M on March 31, 2021.
- Camp4 Therapeutics Corp raised $15M on March 19, 2021.
- Viracta Therapeutics raised $65M on March 10, 2021.
- Exscientia raised $100M (Series C) on March 4, 2021.
- Geneos Therapeutics raised $12M (Series A) on March 3, 2021.
- Enveric Biosciences raised an undisclosed amount on February 24, 2021.
Who to call at Variantyx, and when
A new round usually means Variantyx is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Variantyx raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Variantyx, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Variantyx. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Variantyx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Variantyx raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.